Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Montelukast
Treatment for Asthma
Typical Dosage: 10 mg daily
Effectiveness
65%
Safety Score
75%
Clinical Trials
178
Participants
30K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
75
DangerousModerateSafe
Treatment Details
Dosage Range
10 mg daily
Time to Effect
1-2 weeks
Treatment Duration
lifetime
Evidence Quality
MODERATENumber Needed to Treat (NNT)
12(Treat 12 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
1000(Treat 1000 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$180
Monitoring:$500
Side Effect Mgmt:$25
Total Annual:$705
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$25,000/QALY
QALYs Gained
0.02
Outcome-Based Costs
Cost per Responder
$1,282
Cost per Remission
$4,700
Comparison vs Fluticasone propionate (ICS)
Cost Difference
$-295/year
Less expensive
QALY Difference
-0.08 QALYs
Worse outcomes
Dominance
No dominance
Prescription Access Economics
Annual Societal Loss per Patient
$240
Cost of prescription-only barriers (visits, time, admin, price premium)
Physician Visit Cost
$300/year
Time Cost
$80/year
Travel + wait time
Insurance Admin Cost
$240/year
Prior auth, claims
Rx Price
$180/year
Potential OTC Price
$60/year
Estimated if OTC available
Early Treatment Benefit
+0.05 QALYs
From faster OTC access
Risk Assessment
Misuse Risk
MODERATEMissed Diagnosis Risk
LOWMontelukast Outcomes
for Asthma
Efficacy Outcomes
Overall Effectiveness
+65%
Response Rate
+55%
Remission Rate
+15%
Common Side Effects
Headache
+12%
Abdominal pain
+5%
Neuropsychiatric events
+0.5%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
18 completed trials for Montelukast in Asthma
The Effects of Montelukast on Smokers With Asthma
NCT00712335COMPLETEDPHASE4
105 participants
INTERVENTIONAL
Seoul, South Korea
Started: Feb 1, 2007
Effect of Addition of Oral Montelukast to Standard Treatment in Acute Moderate to Severe Asthma in Children
NCT00565955COMPLETEDPHASE3
116 participants
INTERVENTIONAL
New Delhi, India
Started: Mar 1, 2007
Bioequivalency Study of Montelukast 10 mg Tablets Under Fasted Conditions
NCT01659931COMPLETEDEARLY_PHASE1
34 participants
INTERVENTIONAL
Fargo, United States
Started: Feb 1, 2008
Bioequivalency Study of Montelukast 10 mg Tablets Under Fed Conditions
NCT01659918COMPLETEDEARLY_PHASE1
35 participants
INTERVENTIONAL
Fargo, United States
Started: Feb 1, 2008
Bioequivalency Study of Montelukast Chewable 5 mg Tablets Under Fasted Conditions
NCT01659905COMPLETEDEARLY_PHASE1
35 participants
INTERVENTIONAL
Fargo, United States
Started: Aug 1, 2008
Bioequivalency Study of Montelukast Chewable 5 mg Tablets Under Fed Conditions
NCT01659892COMPLETEDEARLY_PHASE1
36 participants
INTERVENTIONAL
Fargo, United States
Started: Aug 1, 2008
Role of Montelukast in Asthma and Allergic Rhinitis Patients
NCT03380975COMPLETEDPHASE4
600 participants
INTERVENTIONAL
Karachi, Pakistan
Started: Aug 28, 2018
Effects of Montelukast in Asthmatic Children With and Without Food Allergy
NCT01618929COMPLETEDPHASE4
113 participants
INTERVENTIONAL
Ankara, Turkey (Türkiye)
Started: Mar 1, 2013
Sputum Matrix Metalloproteinases (MMP) mRNA and Montelukast
NCT00947453COMPLETEDPHASE2
15 participants
INTERVENTIONAL
Norwich, United Kingdom
Started: Jul 1, 2009
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Inhaled Montelukast (MK-0476) in Participants With Mild or Moderate Asthma (MK-0476-380 AM3)(COMPLETED)
NCT00636207COMPLETEDPHASE1
46 participants
INTERVENTIONAL
Started: Aug 1, 2007
Safety and the Pharmacokinetic Study of Characteristics of MKT-N2 (Montelukast) and Singulair® (Montelukast Sodium)to Treat Asthma
NCT02029313COMPLETEDPHASE1
40 participants
INTERVENTIONAL
Incheon, South Korea
Started: Nov 1, 2013
Singulair(R) In Asthma And Allergic Rhinitis (0476-383)
NCT00545844COMPLETEDPHASE4
313 participants
INTERVENTIONAL
Started: Apr 1, 2007
The Singulair® add-on Study Effectiveness of Adding Montelukast to Inhaled Corticosteroids in Adult Subjects With Uncontrolled Asthma (0476-384)
NCT00755794COMPLETEDPHASE3
800 participants
INTERVENTIONAL
Started: Jun 1, 2006
Change of Airway Hyperresponsiveness to Mannitol and Methacholine in Patients With Asthma
NCT01725360COMPLETEDPHASE4
17 participants
INTERVENTIONAL
Bern, Switzerland
Started: Jan 1, 2007
TEAM (Trial on Efficacy and Quality of Life Among Asthmatic Patient With Montelukast)
NCT03096327COMPLETEDPHASE4
180 participants
INTERVENTIONAL
Karachi, Pakistan
Started: May 1, 2017
Add-on Salmeterol Versus Montelukast in Arg/Arg-16 Asthmatics
NCT00655616COMPLETEDNA
64 participants
INTERVENTIONAL
Dundee, United Kingdom
Started: Aug 1, 2007
Investigation to Identify Predictors of Response to a Treatment With Montelukast
NCT00721240COMPLETEDPHASE4
50 participants
INTERVENTIONAL
Wesel, Germany
Started: Feb 1, 2006
Effect of Montelukast on the Expression and Variation of TGF-β for Children With Mild Persistent Asthma
NCT00536705COMPLETED
112 participants
OBSERVATIONAL
Shanghai, China
Started: Jan 1, 2009
Showing 20 of 179 total trials